GET DAILY SIGNALSLantern Pharma (LTRN): An AI-Driven Path in Precision Oncology
Key Takeaways
- LTRN is the Nasdaq ticker for Lantern Pharma Inc., a clinical-stage oncology biotechnology company headquartered in Dallas, Texas.
- The company develops cancer drug candidates using a proprietary artificial intelligence (AI) platform called RADR® that combines genomics, machine learning, and big data.
- Lantern Pharma is pre-revenue and generates no product sales, funding its research primarily through equity offerings and collaborations.
- Its pipeline is anchored by three clinical-stage candidates — LP-300, LP-184, and LP-284 — plus an antibody drug conjugate (ADC) program in preclinical research.
- Because the company is at an early, cash-burning stage of development, its business profile carries significant clinical, regulatory, and financial risk.
Introduction
Lantern Pharma Inc. (LTRN) is a clinical-stage biotechnology company that is applying artificial intelligence and genomic data to the discovery and development of precision oncology therapies. Rather than relying on traditional trial-and-error drug development, the company has built a data-driven platform designed to identify which cancer patients are most likely to respond to a given drug candidate. This AI-first approach sits at the center of Lantern Pharma's business model and is the primary reason investors follow the company. When I first looked at the setup, I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Company Profile
Lantern Pharma was founded in 2013 and is headquartered in Dallas, Texas, at 1920 McKinney Avenue. The company completed its initial public offering (IPO) on the Nasdaq exchange in June 2020. As a development-stage enterprise, Lantern Pharma employs a small team and maintains a lean operating structure typical of early biotech companies.
The company's core technology is its proprietary RADR® platform, an AI-enabled engine that integrates billions of oncology-relevant data points and uses machine learning algorithms to predict patient responses, guide biomarker selection, and design more targeted clinical trials. The company describes this as a way to "de-risk" development and accelerate the time it takes to move a candidate toward regulatory approval.
Lantern Pharma pursues a dual development strategy. First, it advances de novo, biomarker-guided drug candidates discovered through its AI platform. Second, it seeks to "rescue" historical drug candidates — compounds that were previously tested but deprioritized for efficacy or strategic reasons — by re-evaluating them in more precisely stratified patient populations using genomic and computational tools.
Product Pipeline
Lantern Pharma's portfolio is built around several investigational oncology candidates:
- LP-300 — an investigational therapy being studied in a Phase 2 trial in never-smoker patients with non-small cell lung cancer (NSCLC) adenocarcinoma.
- LP-184 — a drug candidate that has shown activity in multiple solid tumor types, including pancreatic, lung, bladder, and breast cancers, as well as glioblastoma.
- LP-284 — an investigational therapy focused on hematological cancers such as non-Hodgkin's lymphomas, including mantle cell lymphoma.
- ADC program — an antibody drug conjugate program, a therapeutic approach that links an antibody to a cancer-killing drug, currently in preclinical optimization.
In January 2023, the company formed a wholly owned subsidiary, Starlight Therapeutics Inc., to advance LP-184 for central nervous system (CNS) and brain cancer indications, including glioblastoma and rare pediatric CNS cancers. Under this subsidiary, the molecule is also referred to as STAR-001. Lantern Pharma has additionally established research collaborations with organizations such as Oregon Therapeutics, TTC Oncology, and Actuate Therapeutics.
Business Model and Financial Profile
Lantern Pharma is a pre-revenue company, meaning it does not yet generate meaningful product sales. Its financial profile is defined by research and development expenditures and operating losses, which is characteristic of clinical-stage biotechnology firms. The company funds its operations through equity capital raises and, in some cases, collaboration agreements, and it expects to continue incurring losses as its candidates advance through clinical trials. Investors should understand that the company's long-term value is tied to the success of its drug candidates rather than to current revenue or earnings.
Why Investors Follow LTRN
Lantern Pharma attracts attention primarily for its differentiated, AI-driven approach to oncology drug development. The RADR® platform represents a potential competitive advantage by aiming to reduce the cost, time, and failure rate associated with bringing cancer therapies to market. For investors interested in the intersection of biotechnology and artificial intelligence, the company offers exposure to a precision-medicine thesis built on genomics and computational biology.
The company's pipeline also spans multiple high-value oncology indications, including lung cancer, glioblastoma, and lymphomas, giving it several potential shots on goal across distinct disease areas. Its strategy of rescuing historical drug candidates is designed to lower development risk by leveraging existing safety and tolerability data, potentially shortening development timelines compared with entirely new molecules. From what I see, this combination of AI tools and repurposing efforts is worth monitoring closely.
Risks and Important Considerations
Investing in Lantern Pharma involves substantial risk that prospective shareholders should weigh carefully. As a clinical-stage biotech, the company faces the inherent uncertainty of whether its drug candidates will demonstrate sufficient safety and efficacy to secure regulatory approval. Clinical trials frequently fail or are delayed, and none of Lantern Pharma's candidates has yet received marketing approval.
Financially, the company is loss-making and cash-burning, which creates an ongoing need for additional capital and the possibility of shareholder dilution through future equity offerings. The company also faces intense competition from larger, better-capitalized pharmaceutical and biotechnology firms pursuing similar oncology and AI-driven drug development strategies. Regulatory requirements, trial enrollment challenges, and reliance on collaborations add further layers of operational risk. Because the company has no product revenue, its market position is highly dependent on the continued scientific and clinical progress of its pipeline.
Conclusion
Lantern Pharma occupies a distinctive position at the convergence of artificial intelligence and precision oncology. Its RADR® platform and biomarker-guided pipeline differentiate it from more traditional drug developers, while its strategy of rescuing historical candidates aims to make development faster and less costly. At the same time, the company remains a pre-revenue, clinical-stage enterprise whose future depends on the outcomes of ongoing trials and its ability to secure continued funding. For investors comfortable with the risks of early-stage biotechnology, Lantern Pharma represents a focused way to gain exposure to AI-driven cancer drug discovery.
Using AI Tools for Deeper Research
In my own work evaluating names like LTRN, I regularly turn to Tickeron’s AI Screener to compare technical indicators, fundamentals, and AI-generated signals across sectors. It helps surface ideas that align with specific strategies without reviewing every ticker individually. This approach has become a practical part of how I screen for opportunities in biotech and beyond.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
LTRN's RSI Indicator recovers from oversold territory
The RSI Oscillator for LTRN moved out of oversold territory on November 11, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 27 of the 29 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for LTRN just turned positive on October 13, 2026. Looking at past instances where LTRN's MACD turned positive, the stock continued to rise in 40 of 49 cases over the following month. The odds of a continued upward trend are 82%.
Following a +12.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where LTRN advanced for three days, in 200 of 246 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
LTRN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LTRN as a result. In 82 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LTRN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for LTRN entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-2.257) is normal, around the industry mean (3.498). P/E Ratio (-0.348) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. LTRN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LTRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data
Industry Biotechnology
Advertisement